Recurrent Childhood Acute Lymphoblastic Leukemia Completed Phase 1 Trials for Bortezomib (DB00188)

IndicationStatusPhase
DBCOND0028597 (Recurrent Childhood Acute Lymphoblastic Leukemia)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00077467Bortezomib in Treating Young Patients With Refractory or Recurrent LeukemiaTreatment